文献速递神经MR

基于MRI的先进神经影像对治疗后高级别胶质瘤患者神经肿瘤学家临床决策的影响:一项前瞻性调查研究

The Impact of MRI-Based Advanced Neuroimaging on Neurooncologists' Clinical Decision-Making in Patients With Posttreatment High-Grade Glioma: A Prospective Survey-Based Study.
PubMed 文献 · AJR Am J Roentgenol · 2024-08-14

这项前瞻性研究在综合癌症中心纳入63例接受放化疗后的WHO 4级弥漫性胶质瘤成人患者,共70次先进神经影像(灌注和波谱)检查,用于鉴别常规MRI上肿瘤进展与治疗效应。神经肿瘤学家在检查前后填写问卷,44%(31/70)的诊疗事件中实际管理计划与预期计划不同,高于已发表的8.5%(5/59)(p < .001);93%(65/70)的事件中医生认为先进神经影像有帮助。

要点

  • 常规MRI难以鉴别肿瘤进展与治疗效应时,先进神经影像使44%(31/70)的诊疗事件管理计划发生改变。
  • 先进神经影像在93%(65/70;95% CI:87-99%)的诊疗事件中被神经肿瘤学家认为有帮助。
  • 管理计划改变包括临床试验入组(6/8)、更换化疗药(12/19)、手术干预(4/8)和再放疗(1/2)。

核心结论

  • 在常规MRI所见难以鉴别肿瘤进展与治疗效应时,接受先进神经影像检查的成人高级别胶质瘤患者中,神经肿瘤学家的管理计划在相当大比例(44%)的诊疗事件中发生改变;研究结果支持将先进神经影像纳入高级别胶质瘤治疗后监测方案。

研究设计与样本

  • 前瞻性研究,2017年3月1日至2020年10月31日在综合癌症中心进行,纳入63例接受放化疗的WHO 4级弥漫性胶质瘤成人患者,共70次先进神经影像检查(包括多个灌注成像序列和波谱),神经肿瘤学家在每次检查前后填写问卷。

关键影像表现/征象

  • 先进神经影像用于进一步评估常规MRI上难以鉴别的肿瘤进展与治疗效应。
  • 研究未报告具体的影像征象、信号或密度特点。

诊断标准与关键数值

  • 研究未报告敏感度、特异度、AUC、阈值或分级标准;主要比较指标为检查前后管理计划改变的比例44%(31/70;95% CI:33-56%)与已发表频率8.5%(5/59)的比较(p < .001)。

临床应用与阅片要点

  • 在常规MRI难以鉴别肿瘤进展与治疗效应时,先进神经影像(灌注成像和波谱)可影响神经肿瘤学家的临床管理决策,并在93%(65/70;95% CI:87-99%)的诊疗事件中被认为有帮助;研究结果支持将先进神经影像纳入高级别胶质瘤治疗后监测方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Advanced MRI-based neuroimaging techniques, such as perfusion and spectroscopy, have been increasingly incorporated into routine follow-up protocols in patients treated for high-grade glioma (HGG), to help differentiate tumor progression from treatment effect. However, these techniques' influence on clinical management remains poorly understood. OBJECTIVE. The purpose of this article was to evaluate the impact of MRI-based advanced neuroimaging on clinical decision-making in patients with HGG after treatment. METHODS. This prospective study, performed at a comprehensive cancer center from March 1, 2017, to October 31, 2020, included adult patients treated by chemoradiation for WHO grade 4 diffuse glioma who underwent MRI-based advanced neuroimaging (comprising multiple perfusion imaging sequences and spectroscopy) to further evaluate findings on conventional MRI equivocal for tumor progression versus treatment effect. The ordering neurooncologists completed surveys before and after each advanced neuroimaging session. The percent of episodes of care with a change between the intended and actual management plan on the surveys conducted before and after advanced neuroimaging, respectively, was computed and compared with a published percent using the Wald test for independent samples proportions. RESULTS. The study included 63 patients (mean age, 54.6 ± 12.9 [SD] years; 36 women, 27 men) who underwent 70 advanced neuroimaging sessions. Ordering neurooncologists' intended and actual management plans on the surveys completed before and after advanced neuroimaging, respectively, differed in 44% (31/70; 95% CI: 33-56%) of episodes, which differed from the published frequency of 8.5% (5/59) (p < .001). These management plan changes included selection of a different plan for six of eight episodes with an intended plan to enroll patients in a clinical trial, 12 of 19 episodes with an intended plan to change chemotherapeutic agents, four of eight episodes with an intended plan of surgical intervention, and one of two episodes with an intended plan of reirradiation. The ordering neurooncologists found advanced neuroimaging to be helpful in 93% (65/70; 95% CI: 87-99%) of episodes. CONCLUSION. Neurooncologists' management plans changed in a substantial fraction of adult patients with HGG who underwent advanced neuroimaging to further evaluate conventional MRI findings equivocal for tumor progression versus treatment effect. CLINICAL IMPACT. The findings support incorporation of advanced neuroimaging into HGG posttreatment monitoring protocols.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Dagher SA, Liu HL, Ozkara BB, et al. The Impact of MRI-Based Advanced Neuroimaging on Neurooncologists' Clinical Decision-Making in Patients With Posttreatment High-Grade Glioma: A Prospective Survey-Based Study. AJR Am J Roentgenol. 2024. PMID: 39140632. doi:10.2214/AJR.24.31595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。